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Background. Over two million people worldwide suffer from lung cancer, the main sub-type 
(85%) being NSCLC and despite many chemotherapeutics approved for NSCLC, only 2% of 
patients with NSCLC metastatic disease survive 5 years post diagnosis with multidrug 
resistance being the major cause of mortality in NSCLC patients.  
Aim. The overall aim of this project was to evaluate targeted EnGeneIC Dream VectorTM 
(EDVTM) nanocells for loading and delivering small interfering RNA (siRNA) molecules, Polo 
like kinase-1 (PLK1), Ribonucleoside reductase subunit M1 (RRM1) & Kinesin Spindle 
Protein (KSP), in order to silence proteins essential to tumour cell survival and proliferation, 
and to evaluate their therapeutic potential in overcoming the hitherto intractable multiple drug 
resistance in non- small cell lung cancer (NSCLC).  
Methods. The expression of cell cycle genes PLK1, RRM1 & KSP in NSCLC cell lines was 
measured using RT-qPCR and Western Blot. Efficacy of siRNAs targeting PLK1 (siPLK1), 
RRM1 (siRRM1) & KSP (siKSP) transfected into NSCLC cell lines was measured by the MTS 
proliferation assay and Western Blot. Flow cytometric analysis was used to measure apoptosis 
and cell cycle arrest in NSCLC cell lines transfected with the siRNAs targeting PLK1, RRM1 
and KSP. EDVTM nanocells were targeted to the epithelial growth factor receptor (EGFR) and 
the copy number of siRNAs loaded into the nanocells was measured by staining with an RNA 
specific dye and measured on a fluorometer compared to known standards. EDVTM-siRNAs 
were used to treat NSCLC cells lines grown as 3D spheroids using the hanging drop plates 
(Perfecta3D®:HDP1096) and cell proliferation inhibition was assessed using trypan blue cell 
viability assay. The EDVTMs-siRNAs were then tested in vivo using the A549-Dox-R a 
xenograft mouse model, tumours were excised and assessed for gene knockdown by RT-qPCR.  
Results and Conclusion. In this study we show that in vitro and in vivo, EDVTMs can effectively 
deliver targeted-cell cycle-siRNAs to hanging drop 3D spheroids and into a mouse xenograft 
model to inhibit cell and tumour growth, and that EDVTMs can encapsulate and deliver a 
significant siRNA payload directly inside the tumour cells without affecting non-target tissue. 
Overall, this study highlights the exciting possibility that siRNAs against mitotic regulators 
loaded into EDVTMs will be safe alone or in combination with drug-loaded EDVTMs, and may 
overcome drug resistance in NSCLC patients. This project has true translational potential for 
   
 
iv 
both delivering hitherto “undeliverable” functional nucleic acids, and for potentially addressing 
drug-resistance mechanisms in lung cancer. 
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